Chondroitin
Chondroitin sulphate
Also known as: Chondroitin, Chondroitin sulphate, CS, Condrosulf, Structum
Evidence Strength: MODERATE
This ingredient is classified as unclassified risk (GIRI score: 2.5/10). The classification is based on mechanistic and clinical evidence: chondroitin sulfate is thought to inhibit enzymes that degrade cartilage, thereby preserving….
Safety Profile
Common Adverse Effects
- Nausea
- Diarrhea
- Constipation
- Stomach pain
- Headache
Serious Adverse Effects
- Allergic reactions
- Asthma exacerbation
- Edema
Contraindications
- Asthma
- Bleeding disorders
- Prostate cancer
- People taking Warfarin
Interactions
| Drug / Nutrient | Interaction Mechanism | Warning |
|---|---|---|
| Warfarin | increased bleeding risk — monitor INR closely. NSAIDs: potential for enhanced anti | inflammatory effect — use with caution. Anticoagulants: increased bleeding risk — clinical monitoring advised. |
Evidence and Scientific Findings
Ingredient Overview
Biological and Chemical Classification
- Chemical Class
- Glycosaminoglycan
- Biological Class
- Cartilage component
- Natural Source
- Bovine cartilage, Porcine cartilage
- Scientific Name
- Chondroitin sulphate
- Chemical Formula
- C14H21NO14S
- CAS Number
- 9007-28-7
Mechanism of Action
Clinical Evidence of Effectiveness
| Indication | Evidence Level | Summary |
|---|---|---|
| General | Moderate | Clinical trials have shown mixed results regarding the efficacy of chondroitin sulfate in treating osteoarthritis. Some studies indicate a modest reduction in pain and improvement in joint function, while others show no significant benefit. The quality of evidence varies, with some well-conducted randomized controlled trials supporting its use. |
Pharmacokinetics
Recommended Dosage
| Condition / Use | Typical Dose |
|---|---|
| Osteoarthritis | 800-1200 mg daily. Joint pain: 400-800 mg daily. Cartilage support: 500-1000 mg daily. |
Dosage ranges are based on clinical studies and commonly used supplement formulations. Individual requirements may vary.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Chondroitin sulfate is a naturally occurring substance found in the cartilage of animals and humans.
- Evidence consistency: High consistency across studies (100%)
- Chondroitin sulfate is generally considered safe for most adults when used at recommended dosages. However, caution is advised in individuals with asthma, as it may exacerbate symptoms. Pregnant and breastfeeding women should consult a healthcare provider before use. There are no significant regulatory warnings associated with chondroitin sulfate.
- USA/FDA — Approved
The available scientific evidence for Chondroitin indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 12 მარ 2026, 00:52
Evidence Distribution
-
Observational / other LOW evidence YELLOWDevelopment and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease. ↗Berti M et al.. Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease.. Dis Model Mech. 2026. PMID:41783940.PMID 41783940 ↗Journal Dis Model MechYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41783940/
-
Observational / other LOW evidence YELLOWSelective binding of sulphated glycosaminoglycans induces self-assembly of naphthalene diimide into fluorescent nanofibers. ↗Sharma P et al.. Selective binding of sulphated glycosaminoglycans induces self-assembly of naphthalene diimide into fluorescent nanofibers.. Nanoscale. 2026. PMID:41725531.PMID 41725531 ↗Journal NanoscaleYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41725531/
-
Observational / other LOW evidence YELLOWExtracellular matrix remodeling therapeutic strategies to tackle central nervous system diseases. ↗Domingo-Lopez DA et al.. Extracellular matrix remodeling therapeutic strategies to tackle central nervous system diseases.. Neural Regen Res. 2026. PMID:41641774.PMID 41641774 ↗Journal Neural Regen ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41641774/
-
Observational / other LOW evidence YELLOWBifidobacterium longum CBi0703 lysate modulates oxidative stress induced apoptosis and cartilage related gene expression in SW1353 chondrocytes: in vitro insights into the… ↗Mas-Capdevila A et al.. Bifidobacterium longum CBi0703 lysate modulates oxidative stress induced apoptosis and cartilage related gene expression in SW1353 chondrocytes: in vitro insights into the gut joint axis in Osteoarthritis.. Sci Rep. 2026. PMID:41611974.PMID 41611974 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41611974/
-
Observational / other LOW evidence YELLOWMolecular Changes in CSPG and Glial Scar Markers in Response to Subpial Chondroitinase ABC Treatment Following Spinal Cord Injury. ↗Kisucku00e1 A et al.. Molecular Changes in CSPG and Glial Scar Markers in Response to Subpial Chondroitinase ABC Treatment Following Spinal Cord Injury.. Eur J Neurosci. 2026. PMID:41518155.PMID 41518155 ↗Journal Eur J NeurosciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41518155/
-
Observational / other LOW evidence YELLOWDisrupting CSPG-Driven Microglia-Astrocyte Crosstalk Enables Scar-Free Repair in Spinal Cord Injury. ↗Zheng Y et al.. Disrupting CSPG-Driven Microglia-Astrocyte Crosstalk Enables Scar-Free Repair in Spinal Cord Injury.. Adv Sci (Weinh). 2026. PMID:41221600.PMID 41221600 ↗Journal Adv Sci (Weinh)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41221600/
-
Observational / other LOW evidence YELLOWCurcumin-Based Supplement for Vitreous Floaters Post-Nd:YAG Capsulotomy: A Pilot Study. ↗Malandrini A et al.. Curcumin-Based Supplement for Vitreous Floaters Post-Nd:YAG Capsulotomy: A Pilot Study.. Vision (Basel). 2025. PMID:41441556.PMID 41441556 ↗Journal Vision (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41441556/
-
Observational / other LOW evidence YELLOWHyaluronic acid-chondroitin sulphate in overactive bladder: a bridge between pharmacotherapy and advanced therapies. ↗Pischetola A et al.. Hyaluronic acid-chondroitin sulphate in overactive bladder: a bridge between pharmacotherapy and advanced therapies.. Minerva Urol Nephrol. 2025. PMID:41410668.PMID 41410668 ↗Journal Minerva Urol NephrolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41410668/
-
Observational / other LOW evidence YELLOWAntiviral activity of natural and modified hydrocolloids: main sources, susceptible viruses, structure-activity relationship and mechanisms of action. ↗Pereira CSGP et al.. Antiviral activity of natural and modified hydrocolloids: main sources, susceptible viruses, structure-activity relationship and mechanisms of action.. Front Nutr. 2025. PMID:41311803.PMID 41311803 ↗Journal Front NutrYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41311803/
-
Observational / other LOW evidence YELLOWSynergistic effects of creatine supplementation and resistance training in the management of knee osteoarthritis: A narrative review. ↗Osama M et al.. Synergistic effects of creatine supplementation and resistance training in the management of knee osteoarthritis: A narrative review.. J Pak Med Assoc. 2025. PMID:41243927.PMID 41243927 ↗Journal J Pak Med AssocYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41243927/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Chondroitin. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Chondroitin
A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
1 jurisdiction has active restrictions or advisories. Regulatory signals are recorded as Safety Signals and raise the S component.
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.